KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) Operating Expenses (2016 - 2026)

Amgen has reported Operating Expenses over the past 18 years, most recently at $6.0 billion for Q1 2026.

  • For Q1 2026, Operating Expenses fell 14.62% year-over-year to $6.0 billion; the TTM value through Mar 2026 reached $26.7 billion, changed 0.11%, while the annual FY2025 figure was $27.7 billion, 5.75% up from the prior year.
  • Operating Expenses for Q1 2026 was $6.0 billion at Amgen, down from $7.1 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $7.1 billion in Q4 2025 and troughed at $3.7 billion in Q1 2022.
  • A 5-year average of $5.7 billion and a median of $6.5 billion in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: dropped 22.46% in 2022 and later soared 54.3% in 2024.
  • Year by year, Operating Expenses stood at $4.6 billion in 2022, then soared by 50.25% to $6.9 billion in 2023, then decreased by 2.17% to $6.8 billion in 2024, then rose by 5.48% to $7.1 billion in 2025, then decreased by 16.71% to $6.0 billion in 2026.
  • Business Quant data shows Operating Expenses for AMGN at $6.0 billion in Q1 2026, $7.1 billion in Q4 2025, and $7.0 billion in Q3 2025.